Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections.
Invasive fungal infections (IFIs) are an important cause of morbidity and mortality, particularly in patients with underlying risk factors (e.g., neutropenia, cancer chemotherapy, transplantation, AIDS). Although Candida species remain a relevant cause of IFI, other organisms (particularly moulds) h...
| Publicado en: | Infection Vol. 36; no. 4; pp. 296 - 314 |
|---|---|
| Autor principal: | |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Aug2008
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105686226&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105686226 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 03008126 NXO jtl: Infection issn: 03008126 maglogo: N pubinfo: dt: Aug2008 vid: 36 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 105686226 2010019848 10.1007/s15010-008-7357-z NLM18642109 105686226 ppf: 296 ppct: 18 formats: fmt: @attributes: type: P tig: atl: Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. aug: au: Cornely O affil: Klinik I für Innere Medizin, Klinikum der Universität zu Köln, 50924 Cologne, Germany; oliver.cornely@ctuc.de sug: subj: Antifungal Agents Therapeutic Use Fungi Physiology Mycoses Drug Therapy Mycoses Microbiology Mycoses Prevention and Control Drug Resistance, Microbial Fungi Drug Effects Risk Factors ab: Invasive fungal infections (IFIs) are an important cause of morbidity and mortality, particularly in patients with underlying risk factors (e.g., neutropenia, cancer chemotherapy, transplantation, AIDS). Although Candida species remain a relevant cause of IFI, other organisms (particularly moulds) have become increasingly prevalent. In particular, Aspergillus species are the leading cause of mould infections although other moulds including Fusarium species and Zygomycetes are increasing in frequency, and are associated with a high mortality rate. Options available for the prevention and treatment of these infections include standard and liposomal formulations of amphotericin B, but toxicity concerns limit their use; fluconazole is effective for the prevention and treatment of candidiasis but its inactivity against moulds and increasing resistance are limiting factors. Newer azoles, particularly voriconazole and posaconazole, have an enhanced spectrum of activity that includes Candida species, Aspergillus species, Cryptococcus species, dimorphic fungi, Fusarium species, and, for posaconazole, Zygomycetes. Recent data suggest that these agents are highly effective in a variety of clinical settings. Echinocandins have good activity against Candida species and Aspergillus species but their spectrum generally does not include Fusarium species, Cryptococcus species, Trichosporon species, Zygomycetes, and dematiaceous moulds. While these agents are unlikely to exhibit crossresistance with polyenes or azoles, they must be administered intravenously. Knowledge of the pathogenesis of IFIs and the activity, efficacy, and limitations of available treatment options will allow the selection of an appropriate antifungal agent for individual patients. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|